Korean J Pediatr Infect Dis.  2013 Dec;20(3):139-146.

Safety and Reactogenicity of the Inactivated Poliomyelitis Vaccine (Poliorix(TM)) in Korea (2006-2012)

• Sin JB
• Park MS
• Ma SH
• Choi YY
• Shin SM
• Kim WD
• Kuriyakose S
• Ulianov L
• Hardt K

Abstract

OBJECTIVE
As per the requirement of Korean Food and Drug Administration, this post-marketing surveillance was conducted in Korea to evaluate the safety and reactogenicity of Poliorix(TM) following its introduction in 2006.
METHODS
In this open, multicenter study, the vaccine was administered as per the current practice of Korean doctors and in reference to the guidebook by the Korean Pediatric Society and as indicated in the Korean label which was as follows - for primary vaccination three doses were given to infants at ages 2, 4 and 6 months whereas, for the booster dose a single dose was given to children aged 4-6 years. Safety data during this six year surveillance was collected using diary cards which were distributed to the parents to record adverse events.
RESULTS
A total of 639 subjects were enrolled into the study. Of these, 617 subjects and 22 subjects received the vaccine as a primary and booster dose, respectively. At least one unsolicited symptom was reported in 11.4% (73/639) of the subjects during the 7-day follow-up period; upper respiratory tract infection (2.5%;16/639) was the most frequently reported unsolicited symptom. One subject reported at least one unsolicited symptom (gastroenteritis) of grade 3 intensity within the 31-day post-vaccination period. Approximately 1.7% (11/639) of subjects reported 13 serious adverse events (SAEs). All SAEs were resolved by the end of the study.
CONCLUSION
In Korea, primary and booster vaccination with Poliorix(TM) was well-tolerated in healthy subjects when administered according to the prescribing information as part of routine clinical practice.

Keyword

Poliomyelitis; Inactivated polio vaccine; Safety; Reactogenicity; Korea

MeSH Terms

Child
Follow-Up Studies
Humans
Infant
Korea*
Parents
Poliomyelitis*
Respiratory Tract Infections
United States Food and Drug Administration
Vaccination

Figure

• 

  Fig. 1 Study design.

• 

  Fig. 2 Occurrence of each solicited symptom during the 7-day follow-up period for each dose of Poliorix™ (A) local symptoms (B) general symptoms (total vaccinated cohort).

Reference

1. The Global Polio Eradication Initiative. Polio this week: data and monitoring. Cited 2012 Oct 12. Available from http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.

2. World Health Organization. Poliomyelitis: Fact Sheet Number 114. Oct. 2011. cited 2012 Oct 12. Available from: http://www.who.int/mediacentre/factsheets/fs114/en/.

3. Minor P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine. 2009; 27:2649–2652.

4. Dutta A. Epidemiology of poliomyelitis-options and update. Vaccine. 2008; 26:5767–5773.

5. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep. 2009; 58:829–830.

6. World Health Organization. Immunization profile: Republic of Korea. 2012. cited 2012 Oct 12. Available from: http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm.

7. The Korean Pediatric Society. Poliovirus vaccine. In : Lee HJ, editor. Immunization Guideline. 6th ed. Seoul: The Korean Pediatric Society;2008. p. 1–4.

8. World Health Organization. Poliorix™: WHO Package Insert. 2010. cited 2012 Oct 29. Available from: http://www.who.int/immunization_standards/vaccine_quality/Poliorix_package_insert_en_june10.pdf.

9. Advisory Committee on Immunization Program. Epidemiology and prevention of vaccine-preventable disease. Korea Center for Disease Control and Prevention;2005. p. 123–137.

10. Kim SJ, Kim SH, Jee YM, Kim JS. Vaccine associated paralytic poliomyelitis: A case report of flaccid monoparesis after oral polio vaccine. J Korean Med Sci. 2007; 22:362–364.

11. Tebbens RJD, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006; 26:1471–1505.

12. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine. 2008; 26:4978–4983.

13. Li Y, Li R, Ying Z, Wang J, Pan G, Chen X, et al. Immunogenicity and safety of an inactivated poliovirus vaccine in Chinese infants. In : Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID); 16-19 November 2011; The Melbourne, Australia.

14. Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the republic of Korea. Vaccine. 2011; 29:1551–1557.